Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page




    Cutaneous Manifestations of COVID-19: A Systematic Review

    Authors: Giulia Daneshgaran; Danielle P. Dubin; Daniel J. Gould

    doi:10.21203/rs.3.rs-33992/v1 Date: 2020-06-06 Source: ResearchSquare

    Background: The COVID-19 pandemic has affected 4.5 million people and killed over 300,000 patients. Although this virus primarily causes respiratory symptoms, an increasing number of cutaneous manifestations associated with this disease MESHD have been reported.Objective: The aim of this review was to collate and categorize the dermatologic findings reported in COVID-19 patients and identify specific lesions that may facilitate diagnosis and prognostication.Methods: A systematic review of the PubMed database was conducted on May 14th, 2020 using the search terms “Covid-19 skin,” “Covid-19 rash,” “Covid-19 exanthem,” and “Covid-19 chilblains MESHD chilblains HP.” Peer-reviewed publications containing original COVID-19 patient cases and a discussion of the associated cutaneous findings were included in the analysis.Results: The literature search identified 115 records, of which 34 publications describing 996 dermatologic patients were included. Case reports (n=15), case series (n=10) and observational studies (n=7) were the most common publication types. Pseudo- chilblains MESHD chilblains HP (PC) was the most frequent lesion identified (40.4% of cases), appearing in young adults TRANS (mean age TRANS, MA, 23.2 years) after the onset of extracutaneous COVID-19 symptoms (55/100 patients). Erythematous maculopapular rashes (EMR) affected 21.3% of patients, most frequently impacting middle- aged TRANS adults TRANS (MA 53.2 years) and occurring at the same time as non-cutaneous symptoms (110/187 patients). Vesicular rashes (VR) affected 13.0% of patients, appearing in middle- aged TRANS adults TRANS (MA 48.3 years) after the onset of other symptoms (52/84 patients). Urticarial rashes (UR) affected 10.9% of patients, appearing in adults TRANS (MA 38.3 years) and occurring at the same time as non-cutaneous symptoms (46/78 patients). Vascular rashes resembling livedo/ purpura MESHD purpura HP/ necrosis MESHD (LPN) were uncommon (4% of cases), appearing in elderly TRANS patients (MA 77.5 years) and occurring at the same time as non-cutaneous COVID-19 symptoms (18/29 patients). Erythema multiforme MESHD Erythema HP-like eruptions (EME), although infrequent (3.7% of cases), affected mostly children TRANS (MA 12.2 years).Conclusions: VR may suggest an initial diagnosis of COVID-19, PC may be most appropriate for epidemiological uses, and LPN may be a useful prognostic marker for severe disease MESHD. As a potential correlate to disease MESHD severity, prognosis, or infectibility, it is critical that all health care professionals be well-versed in these increasingly common cutaneous manifestations of COVID-19.  

    Severe immune thrombocytopenic purpura MESHD purpura HP in critical COVID-19: a case report

    Authors: Valérie Lévesque; Émilie Milaire; Daniel Corsilli; Benjamin Rioux-Massé; François Martin Carrier

    doi:10.21203/rs.3.rs-32479/v1 Date: 2020-05-29 Source: ResearchSquare

    Purpose: COVID-19 is a new disease MESHD with many undescribed clinical manifestations. Material and methods: We report herein a case of severe immune thrombocytopenic purpura MESHD purpura HP (ITP) in a critical COVID-19 patient.Results: A patient presented a severe episode of immune thrombocytopenia MESHD thrombocytopenia HP (< 10 x 109/L) 20 days after admission for a critical COVID-19. This thrombocytopenia MESHD thrombocytopenia HP was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and high dose dexamethasone to observe an increase in platelet count. Conclusion: COVID-19 may be associated with late presenting severe ITP. Such ITP may also be relatively resistant to first-line agents. Hematological manifestations of COVID-19, such as the ones associated with life-threatening bleeding, must be recognized. 

    The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries

    Authors: Esther E Freeman; Devon E McMahon; Jules B Lipoff; Misha Rosenbach; Carrie Kovarik; Seemal R Desai; Joanna Harp; Junko Takeshita; Lars E French; Henry W Lim; Bruce H Thiers; George J Hruza; Lindy P Fox

    doi:10.1101/2020.05.24.20111914 Date: 2020-05-25 Source: medRxiv

    Question: What are the cutaneous manifestations associated with COVID-19 and do they provide insight into the pathophysiology or prognosis? Findings: In this international registry-based case series of 716 patients representing 31 countries, the most common dermatologic morphologies encountered in the 171 COVID-19 confirmed case TRANS included morbilliform, pernio-like, urticarial, macular erythema MESHD erythema HP, vesicular, papulosquamous, and retiform purpura MESHD purpura HP. Retiform purpura MESHD purpura HP was seen exclusively in critically ill, hospitalized patients. Meaning: COVID-19 is associated with a spectrum of skin findings in affected patients. These cutaneous manifestations may vary depending on the severity of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.